172043-40-2

Upstream product

• 1026279-90-2 N-[5-Bromo-3,4-dicyano-1-(3-methyl-benzyl)-1H-pyrrol-2-yl]-formimidic acid ethyl ester 
• 98130-58-6 2-amino-5-bromo-1H-pyrrole-3,4-dicarbonitrile 
• 172043-33-3 4-amino-6-bromo-7-(3-methylbenzyl)-pyrrolo[2,3-d]pyrimidine-5-carbonitryle 

Relevant academic research and scientific papers

Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action

This invention relates to a novel class of 4,5,6,7-substituted non-nucleoside, non-phosphorylatable pyrrolo[2,3-d]pyrimidines which exhibit both significantly lower levels of cytotoxicity and superior antiviral activity than known nucleoside, non-nucleoside, and non-nucleoside, non-phosphorylatable pyrrolo[2,3-d]pyrimidine derivatives, particularly against human DNA viruses such as cytomegalovirus (HCMV) and herpes simplex virus type 1 (HSV-1). These compounds are represented by the following formula: STR1 wherein R4 is -NH2 or -NHCH3 ; R5 is -CN,-CSNH2, or -CSeNH2 ; R6 is -H or -NH2 ; and R7 is selected from the group consisting of aryls and aralkyls having 6 to 30 carbon atoms; aliphatic oxy-hydrocarbyls having 2 to 15 carbon atoms, lacking free hydroxyl groups and further lacking acyl or acyl derivatized groups; and oxy-hydrocarbyls having 6 to 30 carbon atoms, at least one aryl or aralkyl group, and only one oxy-group; with the proviso that if R5 is -CN and R6 is -H then R4 is -NH2 and R7 is -CH2 C6 H4 -2-CH3.

Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: Influence of various 7-substituents on antiviral activity

A number of 7-substituted 4-aminopyrrolo[2,3-d]pyrimidine-5-carbonitrile, -5-carboxamide, and -5-thiocarboxamide derivatives related to the nucleoside antibiotics toyocamycin and sangivamycin were prepared and tested for their activity against human cytom